Vernalis Share Discussion Threads

[bountyhunter] 12/9/2017 15:58

exactly, insufficient detail on this important matter given that Suir went into liquidation in May 2016 which is more than a year ago now

[romeike] 12/9/2017 13:52

- the Company has progressed a new source of supply.

Again this is all talking out the side of the mouth stuff.

In all likelihood the company has not progressed anything other than negotiating with people who bought the old Suir assets (IQ Pharmatek) for them to continue to supply Moxatag under contract.

The continuation of supply is not particularly interesting, what we want to know is what are the terms on which this drug is being supplied and will Vernalis actually make any significant margin on it. We await details but I would anticipate Vernalis is looking at a much reduced margin on this product.

[bountyhunter] 12/9/2017 11:43

yes encouraging revenue increases but costs need to be reduced and should be some target dates on this bit imho...

"We are also working closely with our partner Tris and the FDA to resubmit the NDAs for CCP-07 and CCP-08 as quickly as possible."

and this is a bit too vague for my liking, again missing a target date other than sometime in 2018...

"The previous manufacturer of Moxatag(R) , Suir, went into liquidation in May 2016. During the year, the Company has progressed a new source of supply and intends to manufacture Moxatag(R) in 2018."

[romeike] 12/9/2017 08:36

So while revenues are indeed better than expected, mostly down to the research department, the company was less than upfront in its update when ir said costs would be below expected. As it turns out costs are up sharply at over 20mil. At the current rate of burn the company has only a few years before being forced to go back to market.

[romeike] 11/9/2017 12:47

Don't hold your breath for any new information tomorrow.

There is still no FDA warning letters appearing for 2017 regarding Tris.

Isn't it about time Vernalis let investors know what the hell is going on?

[fhmktg] 10/9/2017 07:24

Results due Tuesday.As important as the performance of Tuzistra will be clarification on the FDA relationship and a supply agreement for Moxatag.Is it too much to hope for?

[fhmktg] 01/9/2017 00:06

Wow! Mucho buying...... news on the way?

[ffp] 31/8/2017 19:30

With suspenders, you lucky man

[fhmktg] 31/8/2017 18:21

Somebody is stocking up!

[romeike] 22/8/2017 13:56

Share price propped up by bottom feeders. Not going to make any significant moves until a new strategy is made clear and we get some positive news. But yes, at least this isn't PFG of subprime vehicle finance fame - chances of recovery looking slim there. More likely it will end in administration.

[barbar7619] 22/8/2017 12:05

Like PFG another one of Woodford's. He's reputation surely in tatters now!!

[bountyhunter] 16/8/2017 13:52

is that this year or next ;-)

[romeike] 16/8/2017 11:50

If the last update is actually stuck to we should perhaps expect confirmation on 12 September that the sales force have begun active promotion of Moxatag®. I remain sceptical though :(

[romeike] 15/8/2017 13:26

A corporate transaction? Like a buyout? Who would buy Vernalis?

Right now it looks like a good research business with a very expensive fledgling commercial pharma unit that looks like it is in danger of failing, burdened with costs for 100 sales staff, an extremely expensive CEO and all propped up by relatively low revenues from a single seasonal product.

The companies revenue doesn't even cover the CEO's annual bonus. Is this company being run in the best interest of shareholders? I don't think so.

[chrisdgb] 15/8/2017 09:59

Need some kind of corporate transaction, let us hope the big shareholders are pushing for this........

[romeike] 15/8/2017 09:50

Another share price record low. What is Ian Garland and the exec doing about it? We have no idea because they are too busy hiding.

[chrisdgb] 11/8/2017 07:57

Raised to a BUY at Panmure Gordon with 31p price target...........

[bageo] 10/8/2017 19:51

President Trump believes he can fight the 'Opioid Epidemic'

They pay extra for coloured box! I don't.

[romeike] 10/8/2017 10:16

The once a day formulation prevents the overdosing on codeine products that so commonly happens with cough/cold treatments, and controls symptoms at a lower dosage meaning a safer profile / less side effects and much lower risk of addiction. These benefits are well established in healthcare and extended release, lower dose drugs will increasingly be the norm.

Have you heard of the opoid crisis?

While more expensive than multi dose the cost is still generally insignificant. The price the patient actually pays is nothing like the price you suggest above, but that is a matter for the US insurance industry and its uniquely complicated drug pricing structure.

Why do Brits pay over £6 for a colourful branded pack of ibuprofen when you can buy exactly the same medication for under 50p a pack. That makes even less sense to me.

[haroldthegreat] 10/8/2017 08:53

Are the Americans stupid enough to overpay for simple products just because they are long acting formulations ? I can understand paying a few dollars more for the convenience but 100's more ? Woodford must have invested because of the other products.

[chrisdgb] 10/8/2017 08:31

Do we not think that Woodford could something going here....????

One of his private companies reversed in..??

[pugg1ey] 09/8/2017 15:01

I know, just teasing;-)

[romeike] 09/8/2017 14:57

Manufactured by Tris Pharma in New Jersey, USA